What is a stock summary page? Click here for an overview.
Business Description
Insmed Inc
NAICS : 325412
SIC : 2834
ISIN : US4576693075
Share Class Description:
LTS:0JAV: Ordinary SharesDescription
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.25 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 4.03 | |||||
| Debt-to-EBITDA | -1.4 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.36 | |||||
| Beneish M-Score | -2.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.7 | |||||
| 3-Year EBITDA Growth Rate | -13.4 | |||||
| 3-Year EPS without NRI Growth Rate | -13.4 | |||||
| 3-Year FCF Growth Rate | -9.2 | |||||
| 3-Year Book Growth Rate | -22.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 45.37 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 75.54 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.67 | |||||
| 9-Day RSI | 40.69 | |||||
| 14-Day RSI | 43.8 | |||||
| 3-1 Month Momentum % | 16.53 | |||||
| 6-1 Month Momentum % | 10.29 | |||||
| 12-1 Month Momentum % | 193.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.45 | |||||
| Quick Ratio | 5.12 | |||||
| Cash Ratio | 4.82 | |||||
| Days Inventory | 385.95 | |||||
| Days Sales Outstanding | 42.75 | |||||
| Days Payable | 254.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.7 | |||||
| Shareholder Yield % | -7.49 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.43 | |||||
| Operating Margin % | -216.27 | |||||
| Net Margin % | -251.24 | |||||
| FCF Margin % | -194.06 | |||||
| ROE % | -41989.34 | |||||
| ROA % | -54.54 | |||||
| ROIC % | -135.99 | |||||
| 3-Year ROIIC % | -597.89 | |||||
| ROC (Joel Greenblatt) % | -761.08 | |||||
| ROCE % | -62.39 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.9 | |||||
| PB Ratio | 48.56 | |||||
| Price-to-Tangible-Book | 152.84 | |||||
| EV-to-EBIT | -15.36 | |||||
| EV-to-Forward-EBIT | -14.91 | |||||
| EV-to-EBITDA | -15.57 | |||||
| EV-to-Forward-EBITDA | -16.75 | |||||
| EV-to-Revenue | 35.05 | |||||
| EV-to-Forward-Revenue | 28.65 | |||||
| EV-to-FCF | -19.16 | |||||
| Price-to-GF-Value | 2.6 | |||||
| Earnings Yield (Greenblatt) % | -6.5 | |||||
| FCF Yield % | -5.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Insmed Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 363.707 | ||
| EPS (TTM) ($) | -5.59 | ||
| Beta | 1.15 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 2.38 | ||
| Volatility % | 123.04 | ||
| 14-Day RSI | 43.8 | ||
| 14-Day ATR ($) | 2.545261 | ||
| 20-Day SMA ($) | 76.46173 | ||
| 12-1 Month Momentum % | 193.65 | ||
| 52-Week Range ($) | 21.96 - 84.82 | ||
| Shares Outstanding (Mil) | 181 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Insmed Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Insmed Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Insmed Inc Frequently Asked Questions
What is Insmed Inc(LTS:0JAV)'s stock price today?
The current price of LTS:0JAV is $74.89. The 52 week high of LTS:0JAV is $84.82 and 52 week low is $21.96.
When is next earnings date of Insmed Inc(LTS:0JAV)?
The next earnings date of Insmed Inc(LTS:0JAV) is 2025-05-09 Est..
Does Insmed Inc(LTS:0JAV) pay dividends? If so, how much?
Insmed Inc(LTS:0JAV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers